Drug Repurposing Market, By Deployment Mode, By Therapeutic Area, By End Use, By Drug Molecules, By Type of Approach, By Route of Administration, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

Drug Repurposing Market size was valued at US$ 33,018.10 Million in 2024, expanding at a CAGR of 4.30% from 2025 to 2032.

The drug repurposing market focuses on identifying and developing new therapeutic uses for existing or previously approved drugs, allowing for faster and more cost-effective treatment development than traditional drug discovery. Rising R&D costs and the urgent need to accelerate therapies for complex and rare diseases are the primary drivers of market growth. The increasing use of artificial intelligence and real-world data to discover novel drug-disease relationships is a major market trend. However, regulatory uncertainties, intellectual property limitations, and data validation challenges all act as significant barriers. Despite these obstacles, a greater emphasis on rare diseases, oncology, and emerging infectious conditions presents significant opportunities for drug repurposing, which reduces development timelines, lowers failure risk, and maximizes the clinical value of existing pharmaceutical assets.

Drug Repurposing Market- Market Dynamics

Rising Healthcare Expenditure Driving Drug Repurposing Market Growth

The increasing level of global healthcare expenditure is a major driver of the drug repurposing market's growth. Healthcare spending includes prevention, diagnosis, treatment, rehabilitation, and healthcare administration, and it is increasing due to rising medical costs, technological advancements, and increased demand for healthcare services. Increased healthcare spending allows for more investment in research activities, clinical trials, and data-driven studies, all of which are critical for discovering new therapeutic indications for existing drugs. This trend benefits drug repurposing significantly because it provides a less expensive and faster alternative to traditional drug discovery. According to the 2021-2030 National Health Expenditure report published by the United States Centers for Medicare & Medicaid Services in March 2022, national health spending is expected to increase at an average annual rate of 5.1%, reaching nearly USD 6.8 trillion by 2030. Rising Medicare and Medicaid spending boosts funding availability for repurposing research, hastening market expansion.

Drug Repurposing Market- Segmentation Analysis:

The Global Drug Repurposing Market is segmented on the basis of Deployment Mode, Therapeutic Area, End Use, Drug Molecules, Type of Approach, Route of Administration, and Region.

Oncology represents a significant share of the market, driven by the high global prevalence of cancer and the substantial unmet need for more effective and accessible treatment options. A growing number of existing oncology drugs, as well as therapies originally approved for non-oncologic indications, are being evaluated for new cancer applications by leveraging their established safety and efficacy profiles to accelerate development timelines. This strategy significantly reduces both the cost and time required to introduce new cancer treatments. For example, in December 2024, researchers at UT Southwestern reported that an FDA-approved therapy for multiple myeloma and lymphoma demonstrated tumor-shrinking effects in patients with KRAS-mutated non-small cell lung cancer. In parallel, initiatives such as the ReDO Project are advancing the repurposing of non-cancer drugs for oncology, with a focus on delivering effective, low-toxicity treatment alternatives.

Based on End Use, Pharmaceutical and biotechnology companies account for the majority of revenue share. These companies have established infrastructure, extensive R&D capabilities, and regulatory expertise, allowing them to effectively repurpose existing drugs for new indications. Their vast financial resources make it easier to fund clinical trials and acquire promising drug candidates. Furthermore, the growing need to fill gaps in medical care and the demand for low-cost therapies have prompted these companies to investigate repurposing strategies. The United States Food and Drug Administration (FDA) approved baricitinib in May 2022 for the treatment of hospitalized adults who require varying degrees of respiratory support as a result of COVID-19. This approval followed an earlier Emergency Use Authorization (EUA) issued in November 2020 for the combination of baricitinib and remdesivir in the treatment of COVID-19 in hospitalized adults and pediatric patients. The approval was based on results from the Adaptive COVID-19 Treatment Trial (ACTT-2), which showed that the combination therapy shortened recovery time and improved clinical outcomes in hospitalized patients..

Drug Repurposing Market- Geographical Insights

North America dominates the market. The expansion is fueled by advanced research infrastructure, supportive regulatory landscapes, and faster approval for repurposed drugs. In addition, this region is promoting strong collaborations between AI startups, research centers, and large pharmaceutical companies to develop repurposed drugs for various diseases. In August 2025, Fifty 1 AI Labs, a subsidiary of Fifty 1 Labs, Inc., collaborated with LUNR Aerospace to develop AI-powered drug repurposing initiatives for space medicine.

United States Drug Repurposing Market- Country Insights

The United States is the major North American market, driven by a thriving pharmaceutical and biotechnology industry that is investing in AI-powered drug discovery platforms. For example, in September 2025, Massachusetts-based Lila Sciences raised USD 235 million in a Series A round to expand its AI-powered autonomous laboratories. The funds are raised to expand Lila's "AI Science Factories" in Boston, San Francisco, and London, where AI models develop hypotheses, run experiments, learn from results, and iterate from start to finish. The nation's strong financing environment, combined with mature collaborations between academia and AI solution providers, continues to drive large-scale repurposing programs.

Drug Repurposing Market- Competitive Landscape:

The drug repurposing market is distinguished by collaborations among pharmaceutical companies, biotech firms, research institutions, and technology providers aimed at discovering new therapeutic applications for existing medications. Strategic partnerships, licensing agreements, and investments in advanced computational platforms that accelerate drug repurposing research all have an impact on competition. Companies are increasingly relying on artificial intelligence, real-world evidence, and big data analytics to improve target identification, streamline clinical validation, and lower development costs. Regulatory alignment and shared research frameworks also have an impact on competitive positioning. Novartis AG, Pfizer Inc., Eli Lilly and Company, and Bayer AG are key players driving innovation and commercial activity in the drug repurposing market. These organizations use extensive compound libraries, global R&D capabilities, and strategic alliances to broaden their repurposed drug portfolios and increase market visibility.

In April 2025, Novartis agreed to acquire Regulus Therapeutics, a San Diego-based clinical-stage biopharmaceutical company focused on microRNA therapies. Faburden, Regulus' leading asset, targets miR-17 and has the potential to be a first-in-class treatment for autosomal dominant polycystic kidney disease (ADPKD). This acquisition complements Novartis' focus on renal disease and will increase its expertise in this therapeutic area. The acquisition expands Novartis' portfolio by incorporating novel approaches to treating kidney diseases.

Recent Developments:

In April 2025, Qualthera Health Corporation, which is dedicated to establishing a nationwide network of quality, patient-centered compounding pharmacies, has announced the official launch of Qualthera Pharmaceuticals Ltd. Co., a research-driven subsidiary focused on drug repurposing and innovative delivery systems. This expansion is a significant step forward in accelerating pharmaceutical innovation by leveraging real-world patient insights to create new therapies with streamlined development.

In June 2024, BioXcel Therapeutics used artificial intelligence-based drug repurposing to discover new applications for drug candidates that had stalled in development. The company accelerates therapeutic innovation by integrating approved and established drugs, clinically validated candidates, big data, and proprietary machine learning algorithms. It is focused on research and development costs, market access, and growth in neurology and immuno-oncology within the drug repurposing market.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DRUG REPURPOSING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Eli Lilly and Company
GSK plc
Amgen Inc.
Biogen Inc.
Pfizer Inc.
Roche Holding AG
Novartis AG
AbbVie
Amgen
Boehringer Ingelheim
Cyclica
GlaxoSmithKline
Vertex Pharmaceuticals
Melior Discovery
Pharnext
Recursion Pharmaceuticals
Revolution Medicines
Sanofi
Schwarz Pharma
Valence Discovery
Bayer AG
Teva Pharmaceutical
Others

GLOBAL DRUG REPURPOSING MARKET, BY DEPLOYMENT MODE- MARKET ANALYSIS, 2019 - 2032

On-premises
Cloud-based

GLOBAL DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

Oncology
Cardiovascular Diseases
Infectious Diseases
Rare Diseases
Neurology
Immunology
Metabolic Disorders
Others

GLOBAL DRUG REPURPOSING MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032

Contract Research Organizations (CROs)
Pharmaceutical & Biotechnology Companies
Healthcare Providers
Academic & Research Institutes
Others

GLOBAL DRUG REPURPOSING MARKET, BY DRUG MOLECULES- MARKET ANALYSIS, 2019 - 2032

Peptides
Biologics
Vaccines
Conventional Small Molecules
Others

GLOBAL DRUG REPURPOSING MARKET, BY TYPE OF APPROACH- MARKET ANALYSIS, 2019 - 2032

Target-centric
Disease-centric
Drug-centric

GLOBAL DRUG REPURPOSING MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Intravenous
Oral
Other routes of administration

GLOBAL DRUG REPURPOSING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV5994

1. Drug Repurposing Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Drug Repurposing Market Snippet by Deployment Mode
- 2.1.2. Drug Repurposing Market Snippet by Therapeutic Area
- 2.1.3. Drug Repurposing Market Snippet by End Use
- 2.1.4. Drug Repurposing Market Snippet by Drug Molecules
- 2.1.5. Drug Repurposing Market Snippet by Type of Approach
- 2.1.6. Drug Repurposing Market Snippet by Route of Administration
- 2.1.7. Drug Repurposing Market Snippet by Country
- 2.1.8. Drug Repurposing Market Snippet by Region
2.2. Competitive Insights

3. Drug Repurposing Key Market Trends

3.1. Drug Repurposing Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Drug Repurposing Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Drug Repurposing Market Opportunities
3.4. Drug Repurposing Market Future Trends

4. Drug Repurposing Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Drug Repurposing Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Drug Repurposing Market Landscape

6.1. Drug Repurposing Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Drug Repurposing Market - By Deployment Mode

7.1. Overview
- 7.1.1. Segment Share Analysis, By Deployment Mode, 2024 & 2032 (%)
- 7.1.2. On-premises
- 7.1.3. Cloud-based

8. Drug Repurposing Market - By Therapeutic Area

8.1. Overview
- 8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
- 8.1.2. Oncology
- 8.1.3. Cardiovascular Diseases
- 8.1.4. Infectious Diseases
- 8.1.5. Rare Diseases
- 8.1.6. Neurology
- 8.1.7. Immunology
- 8.1.8. Metabolic Disorders
- 8.1.9. Others

9. Drug Repurposing Market - By End Use

9.1. Overview
- 9.1.1. Segment Share Analysis, By End Use, 2024 & 2032 (%)
- 9.1.2. Contract Research Organizations (CROs)
- 9.1.3. Pharmaceutical & Biotechnology Companies
- 9.1.4. Healthcare Providers
- 9.1.5. Academic & Research Institutes
- 9.1.6. Others

10. Drug Repurposing Market - By Drug Molecules

10.1. Overview
- 10.1.1. Segment Share Analysis, By Drug Molecules, 2024 & 2032 (%)
- 10.1.2. Peptides
- 10.1.3. Biologics
- 10.1.4. Vaccines
- 10.1.5. Conventional Small Molecules
- 10.1.6. Others

11. Drug Repurposing Market - By Type of Approach

11.1. Overview
- 11.1.1. Segment Share Analysis, By Type of Approach, 2024 & 2032 (%)
- 11.1.2. Target-centric
- 11.1.3. Disease-centric
- 11.1.4. Drug-centric

12. Drug Repurposing Market - By Route of Administration

12.1. Overview
- 12.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
- 12.1.2. Intravenous
- 12.1.3. Oral
- 12.1.4. Other routes of administration

13. Drug Repurposing Market- By Geography

13.1. Introduction
- 13.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
13.2. North America
- 13.2.1. Overview
- 13.2.2. Drug Repurposing Key Manufacturers in North America
- 13.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.2.4. North America Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
- 13.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 13.2.6. North America Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 13.2.7. North America Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
- 13.2.8. North America Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
- 13.2.9. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.2.10. U.S.
  - 13.2.10.1. Overview
  - 13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.2.10.3. U.S. Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.2.10.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.2.10.5. U.S. Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.2.10.6. U.S. Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.2.10.7. U.S. Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.2.10.8. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.2.11. Canada
  - 13.2.11.1. Overview
  - 13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.2.11.3. Canada Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.2.11.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.2.11.5. Canada Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.2.11.6. Canada Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.2.11.7. Canada Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.2.11.8. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3. Europe
- 13.3.1. Overview
- 13.3.2. Drug Repurposing Key Manufacturers in Europe
- 13.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.3.4. Europe Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
- 13.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 13.3.6. Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 13.3.7. Europe Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
- 13.3.8. Europe Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
- 13.3.9. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.10. Germany
  - 13.3.10.1. Overview
  - 13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.10.3. Germany Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.10.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.10.5. Germany Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.10.6. Germany Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.10.7. Germany Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.10.8. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.11. UK
  - 13.3.11.1. Overview
  - 13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.11.3. UK Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.11.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.11.5. UK Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.11.6. UK Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.11.7. UK Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.11.8. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.12. France
  - 13.3.12.1. Overview
  - 13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.12.3. France Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.12.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.12.5. France Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.12.6. France Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.12.7. France Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.12.8. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.13. Italy
  - 13.3.13.1. Overview
  - 13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.13.3. Italy Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.13.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.13.5. Italy Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.13.6. Italy Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.13.7. Italy Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.13.8. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.14. Spain
  - 13.3.14.1. Overview
  - 13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.14.3. Spain Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.14.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.14.5. Spain Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.14.6. Spain Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.14.7. Spain Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.14.8. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.15. The Netherlands
  - 13.3.15.1. Overview
  - 13.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.15.3. The Netherlands Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.15.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.15.5. The Netherlands Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.15.6. The Netherlands Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.15.7. The Netherlands Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.15.8. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.16. Sweden
  - 13.3.16.1. Overview
  - 13.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.16.3. Sweden Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.16.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.16.5. Sweden Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.16.6. Sweden Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.16.7. Sweden Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.16.8. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.17. Russia
  - 13.3.17.1. Overview
  - 13.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.17.3. Russia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.17.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.17.5. Russia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.17.6. Russia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.17.7. Russia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.17.8. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.18. Poland
  - 13.3.18.1. Overview
  - 13.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.18.3. Poland Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.18.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.18.5. Poland Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.18.6. Poland Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.18.7. Poland Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.18.8. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.19. Rest of Europe
  - 13.3.19.1. Overview
  - 13.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.19.3. Rest of the Europe Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.19.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.19.5. Rest of the Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.19.6. Rest of the Europe Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.19.7. Rest of the Europe Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.19.8. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4. Asia Pacific (APAC)
- 13.4.1. Overview
- 13.4.2. Drug Repurposing Key Manufacturers in Asia Pacific
- 13.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.4.4. APAC Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
- 13.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 13.4.6. APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 13.4.7. APAC Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
- 13.4.8. APAC Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
- 13.4.9. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.10. China
  - 13.4.10.1. Overview
  - 13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.10.3. China Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.10.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.10.5. China Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.10.6. China Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.10.7. China Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.10.8. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.11. India
  - 13.4.11.1. Overview
  - 13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.11.3. India Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.11.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.11.5. India Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.11.6. India Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.11.7. India Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.11.8. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.12. Japan
  - 13.4.12.1. Overview
  - 13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.12.3. Japan Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.12.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.12.5. Japan Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.12.6. Japan Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.12.7. Japan Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.12.8. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.13. South Korea
  - 13.4.13.1. Overview
  - 13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.13.3. South Korea Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.13.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.13.5. South Korea Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.13.6. South Korea Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.13.7. South Korea Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.13.8. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.14. Australia
  - 13.4.14.1. Overview
  - 13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.14.3. Australia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.14.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.14.5. Australia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.14.6. Australia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.14.7. Australia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.14.8. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.15. Indonesia
  - 13.4.15.1. Overview
  - 13.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.15.3. Indonesia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.15.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.15.5. Indonesia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.15.6. Indonesia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.15.7. Indonesia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.15.8. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.16. Thailand
  - 13.4.16.1. Overview
  - 13.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.16.3. Thailand Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.16.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.16.5. Thailand Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.16.6. Thailand Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.16.7. Thailand Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.16.8. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.17. Philippines
  - 13.4.17.1. Overview
  - 13.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.17.3. Philippines Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.17.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.17.5. Philippines Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.17.6. Philippines Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.17.7. Philippines Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.17.8. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.18. Rest of APAC
  - 13.4.18.1. Overview
  - 13.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.18.3. Rest of APAC Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.18.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.18.5. Rest of APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.18.6. Rest of APAC Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.18.7. Rest of APAC Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.18.8. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5. Latin America (LATAM)
- 13.5.1. Overview
- 13.5.2. Drug Repurposing Key Manufacturers in Latin America
- 13.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.5.4. LATAM Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
- 13.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 13.5.6. LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 13.5.7. LATAM Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
- 13.5.8. LATAM Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
- 13.5.9. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.10. Brazil
  - 13.5.10.1. Overview
  - 13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.10.3. Brazil Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.5.10.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.5.10.5. Brazil Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.5.10.6. Brazil Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.5.10.7. Brazil Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.5.10.8. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.11. Mexico
  - 13.5.11.1. Overview
  - 13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.11.3. Mexico Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.5.11.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.5.11.5. Mexico Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.5.11.6. Mexico Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.5.11.7. Mexico Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.5.11.8. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.12. Argentina
  - 13.5.12.1. Overview
  - 13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.12.3. Argentina Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.5.12.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.5.12.5. Argentina Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.5.12.6. Argentina Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.5.12.7. Argentina Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.5.12.8. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.13. Colombia
  - 13.5.13.1. Overview
  - 13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.13.3. Colombia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.5.13.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.5.13.5. Colombia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.5.13.6. Colombia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.5.13.7. Colombia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.5.13.8. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.14. Rest of LATAM
  - 13.5.14.1. Overview
  - 13.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.14.3. Rest of LATAM Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.5.14.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.5.14.5. Rest of LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.5.14.6. Rest of LATAM Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.5.14.7. Rest of LATAM Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.5.14.8. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6. Middle East and Africa
- 13.6.1. Overview
- 13.6.2. Drug Repurposing Key Manufacturers in Middle East and Africa
- 13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.6.4. Middle East and Africa Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
- 13.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 13.6.6. Middle East and Africa Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 13.6.7. Middle East and Africa Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
- 13.6.8. Middle East and Africa Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
- 13.6.9. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.10. Saudi Arabia
  - 13.6.10.1. Overview
  - 13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.10.3. Saudi Arabia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.10.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.10.5. Saudi Arabia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.10.6. Saudi Arabia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.10.7. Saudi Arabia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.10.8. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.11. United Arab Emirates
  - 13.6.11.1. Overview
  - 13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.11.3. United Arab Emirates Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.11.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.11.5. United Arab Emirates Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.11.6. United Arab Emirates Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.11.7. United Arab Emirates Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.11.8. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.12. Israel
  - 13.6.12.1. Overview
  - 13.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.12.3. Israel Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.12.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.12.5. Israel Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.12.6. Israel Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.12.7. Israel Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.12.8. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.13. Turkey
  - 13.6.13.1. Overview
  - 13.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.13.3. Turkey Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.13.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.13.5. Turkey Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.13.6. Turkey Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.13.7. Turkey Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.13.8. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.14. Algeria
  - 13.6.14.1. Overview
  - 13.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.14.3. Algeria Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.14.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.14.5. Algeria Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.14.6. Algeria Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.14.7. Algeria Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.14.8. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.15. Egypt
  - 13.6.15.1. Overview
  - 13.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.15.3. Egypt Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.15.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.15.5. Egypt Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.15.6. Egypt Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.15.7. Egypt Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.15.8. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.16. Rest of MEA
  - 13.6.16.1. Overview
  - 13.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.16.3. Rest of MEA Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.16.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.16.5. Rest of MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.16.6. Rest of MEA Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.16.7. Rest of MEA Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.16.8. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)

14. Key Vendor Analysis- Drug Repurposing Industry

14.1. Competitive Benchmarking
- 14.1.1. Competitive Dashboard
- 14.1.2. Competitive Positioning
14.2. Company Profiles
- 14.2.1. Eli Lilly and Company
- 14.2.2. GSK plc
- 14.2.3. Amgen Inc.
- 14.2.4. Biogen Inc.
- 14.2.5. Pfizer Inc.
- 14.2.6. Roche Holding AG
- 14.2.7. Novartis AG
- 14.2.8. AbbVie
- 14.2.9. Amgen
- 14.2.10. Boehringer Ingelheim
- 14.2.11. Cyclica
- 14.2.12. GlaxoSmithKline
- 14.2.13. Vertex Pharmaceuticals
- 14.2.14. Melior Discovery
- 14.2.15. Pharnext
- 14.2.16. Recursion Pharmaceuticals
- 14.2.17. Revolution Medicines
- 14.2.18. Sanofi
- 14.2.19. Schwarz Pharma
- 14.2.20. Valence Discovery
- 14.2.21. Bayer AG
- 14.2.22. Teva Pharmaceutical
- 14.2.23. Others

15. 360 Degree Analyst View

16. Appendix

16.1. Research Methodology
16.2. References
16.3. Abbreviations
16.4. Disclaimer
16.5. Contact Us